TRIM-edicine

Executive Summary

TRIM-edicine is a privately held biologics company headquartered in Cambridge, Massachusetts, founded in 2019. The company is focused on developing novel therapeutics targeting TRIM (tripartite motif) proteins, a family of E3 ubiquitin ligases implicated in various diseases including cancer, inflammation, and viral infections. Leveraging its proprietary platform, TRIM-edicine aims to modulate TRIM protein activity to restore cellular homeostasis. As a preclinical-stage company, it has not yet disclosed specific pipeline candidates or financing details. Given the early stage and limited public information, the company's progress and potential remain speculative.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round60% success
• H1 2027Lead Program Nomination and Preclinical Data40% success
• 2027Research Partnership or Collaboration50% success